Dr. Alison K. Conlin
Claim this profileProvidence Portland Medical Center
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
179 drugs studied
About Alison K. Conlin
Education:
- Obtained MD (Doctor of Medicine) from Oregon Health & Science University in 2015.
- Completed Residency in Internal Medicine at Providence Portland Medical Center in 2018.
- Board Certified in Internal Medicine by the American Board of Internal Medicine.
Experience:
- Currently practices as an internal medicine physician at Providence Portland Medical Center.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderHER2 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Alison K. Conlin is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
More about Alison K. Conlin
Clinical Trial Related4 years of experience running clinical trials · Led 103 trials as a Principal Investigator · 57 Active Clinical TrialsTreatments Alison K. Conlin has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Ipilimumab
- Paclitaxel
- Fluorouracil
Breakdown of trials Alison K. Conlin has run
Cancer
Breast Cancer
Tumors
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alison K. Conlin specialize in?
Alison K. Conlin focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Alison K. Conlin currently recruiting for clinical trials?
Yes, Alison K. Conlin is currently recruiting for 54 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Alison K. Conlin has studied deeply?
Yes, Alison K. Conlin has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Alison K. Conlin?
Apply for one of the trials that Alison K. Conlin is conducting.
What is the office address of Alison K. Conlin?
The office of Alison K. Conlin is located at: Providence Portland Medical Center, Portland, Oregon 97213 United States. This is the address for their practice at the Providence Portland Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.